Rejuvenating Alzheimer’s R&D
How can we encourage companies to pursue clinical research for CNS disorders?
Maryam Mahdi | | Quick Read
Developing drugs for chronic diseases of aging is notoriously difficult. But addressing the health burden associated with such conditions is becoming increasingly urgent as the world’s population ages (1). The Alzheimer’s Drug Discovery Foundation (ADDF) highlights the need to focus on neurodegenerative disorders and to date has invested more than US$150 million to fund over 626 Alzheimer’s drug discovery programs and clinical trials in 19 countries (2).
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine